What happened with EXEL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Exelixis Inc discovers, develops and sells medicines for difficult-to-treat cancers. Its business centers on cabozantinib, sold as CABOMETYX tablets and COMETRIQ capsules. CABOMETYX, used for cancers including advanced kidney cancer, supplies most of the company’s revenue; COMETRIQ contributes much less. Major product customers include affiliates of Cencora and McKesson, making these relationships important to its U.S. sales.
Outside the United States, Exelixis receives royalties tied to its partners’ cabozantinib sales. Ipsen sells the medicines outside the United States and Japan, while Takeda handles Japan. This income depends on those partners securing approvals, gaining access to reimbursement and investing in commercialization.
The business depends heavily on doctors continuing to prescribe CABOMETYX in its approved uses and on government health programs and private insurers covering treatment. Patients generally cannot afford these medicines without coverage. To obtain coverage through certain U.S. government programs, Exelixis must provide required rebates or discounts, which limit what it keeps from sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Exelixis hinges on cabozantinib demand and competing treatment data, so watch two companies missing here: Ipsen drives most overseas royalties, while Eisai competes in kidney and thyroid cancer.
Bristol Myers Squibb both supports and challenges Exelixis's kidney cancer drug sales: its nivolumab pairs with CABOMETYX, while nivolumab plus ipilimumab competes for the same patients. Watch adoption and treatment duration of the CABOMETYX combination, since Exelixis says longer treatment drove refills.
Merck competes for Exelixis's advanced kidney cancer patients with pembrolizumab combinations and belzutifan, putting CABOMETYX sales up against its prescription cancer medicines. Results from these treatments are the Merck news to watch for CABOMETYX's competitive position.
Pfizer competes with Exelixis for cancer medicine sales through an axitinib-containing kidney cancer regimen and sunitinib for neuroendocrine tumors. Watch these treatments in advanced kidney cancer and previously treated advanced neuroendocrine tumors—the patient groups supporting CABOMETYX demand.
Novartis competes for CABOMETYX patients with everolimus in kidney cancer and neuroendocrine tumors, and lutetium Lu177 dotatate in neuroendocrine tumors. Watch where its treatments fit in the sequence of care for previously treated advanced neuroendocrine tumors; Exelixis says changing treatment choices make the sales impact difficult to predict.
AstraZeneca competes with Exelixis in liver cancer medicines and is developing savolitinib plus durvalumab for the kidney cancer market targeted by zanzalintinib. Watch that combination's trial results in previously untreated advanced non-clear cell kidney cancer, where Exelixis's zanzalintinib plus nivolumab is also being tested.
Takeda sells Exelixis's cabozantinib in Japan and pays Exelixis a share of sales as royalties, but its fruquintinib also competes with Exelixis's prospective colorectal cancer regimen. Japanese cabozantinib sales directly feed Exelixis's royalty revenue, which was $13.2 million from Takeda in 2025.
Agenus's experimental botensilimab–balstilimab cancer treatment competes with Exelixis's zanzalintinib combination for refractory colorectal cancer patients. Watch its clinical results, not access-program revenue as a sign of approval: Agenus began earning revenue from authorized treatment access in 2025, but those programs do not constitute marketing approval.
Royalty Pharma receives a percentage of cabozantinib sales, so demand for Exelixis's main revenue-generating drugs also supports its royalty income. Exelixis pays it 3% of Ipsen and Takeda's net cabozantinib sales; those payments rose to $22.8 million in 2025 as the underlying sales increased.
Novartis AG earningsNVS
Novartis’s report may show whether its treatments are gaining ground in later-line neuroendocrine tumors, where they compete with CABOMETYX for patients.
Look for what Novartis says about use of its treatments in previously treated advanced neuroendocrine tumors and how treatment choices are shifting. Greater use could leave CABOMETYX less room to win patients; weaker use could mean less pressure from those options. Novartis’s overall results may not isolate this patient group or treatment sequence, so treat them as a signal, not a direct measure of CABOMETYX use.
Exelixis Inc earningsThis company
CABOMETYX drives most of Exelixis’s revenue, and this report will show whether U.S. demand is still translating into net product sales.
Read CABOMETYX unit sales alongside net product revenue after discounts and rebates. If units rise and net revenue follows, more treatment demand is turning into sales. If units stall or fall, or discounts and rebates absorb the sales growth, Exelixis’s main revenue engine looks more vulnerable.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report may show whether kidney cancer treatment demand is supporting the nivolumab–CABOMETYX combination or shifting toward a competing regimen.
Watch Bristol Myers Squibb’s comments on kidney cancer treatment demand and regimen choices. Continued use of nivolumab with CABOMETYX could support patients staying on treatment and refilling, helping Exelixis’s sales; a shift toward the competing nivolumab-plus-ipilimumab regimen could weaken that support. Bristol Myers Squibb may not report use of either regimen separately, so its overall results are only an indirect signal.
Takeda Pharmaceutical Company Limited earningsTAK
Takeda sells cabozantinib in Japan and pays royalties to Exelixis, so its report may signal whether that source of Exelixis revenue is growing.
Look for Takeda’s comments on cabozantinib sales in Japan. Stronger sales would support the royalties Exelixis earns there; weaker sales would reduce that contribution. Takeda may not break out cabozantinib separately, so growth in its overall business does not by itself prove that Exelixis’s Japan royalties are rising.
